Table 1.

In vitro antitumor activity of 5-fluorouracil, afatinib, celecoxib, and the tested compounds.

Compd No.	IC50 (μM)a
	HepG2b	MCF-7c	HCT-116d	Caco-2e
5-FU	7.91 ± 0.28	5.43 ± 0.20	5.32 ± 0.17	6.85 ± 0.34
Afatinib	5.4 ± 0.25	7.1 ± 0.49	6.2 ± 0.67	7.7 ± 0.57
Celecoxib	25.6 ± 2.3	31.28 ± 2.5	29.54 ± 2.1	42.74 ± 3.1
1a	85.12 ± 4.53	80.41 ± 4.58	89.63 ± 4.68	94.83 ± 4.92
1b	>100	>100	97.56 ± 5.12	>100
2a	59.83 ± 3.55	48.11 ± 3.15	61.29 ± 3.97	72.19 ± 4.06
2b	9.36 ± 0.79	11.86 ± 1.13	18.71 ± 1.50	21.73 ± 1.90
3a	68.75 ± 3.87	63.61 ± 3.62	78.11 ± 4.08	76.52 ± 4.38
3b	10.52 ± 0.98	13.73 ± 1.19	23.76 ± 1.80	26.81 ± 2.17
4a	71.08 ± 4.11	73.65 ± 3.92	85.40 ± 4.57	80.20 ± 4.50
4b	63.62 ± 3.91	46.52 ± 2.84	76.54 ± 4.22	68.75 ± 3.79
5a	36.75 ± 2.70	42.61 ± 2.67	51.17 ± 3.71	63.78 ± 3.58
5b	19.74 ± 1.57	28.90 ± 1.58	39.52 ± 2.61	35.60 ± 2.62
6a	26.76 ± 2.08	6.11 ± 0.31	46.92 ± 3.23	10.16 ± 0.92
6b	>100	95.26 ± 4.96	91.22 ± 4.96	>100
7a	7.86 ± 0.39	9.65 ± 0.96	14.58 ± 1.24	18.13 ± 1.73
7b	14.91 ± 1.38	17.10 ± 1.40	34.05 ± 2.25	29.14 ± 2.45
8a	7.35 ± 0.34	8.62 ± 0.72	9.73 ± 0.85	15.44 ± 1.37
8b	22.30 ± 1.96	34.09 ± 2.07	46.71 ± 2.93	43.79 ± 2.96

^aIC₅₀, compound concentration required to inhibit tumour cell proliferation by 50% (mean ± SD), n = 3.

^bHuman hepato-cellular carcinoma cell line (HepG2).

^cHuman breast adenocarcinoma cell line (MCF-7).

^dHuman colon cancer cell line (HCT-116).

^eHuman colorectal cancer cell line (Caco-2).

IC₅₀, (μM): 1–10 (very strong), 11–25 (strong), 26–50 (moderate), 51–100 (weak), above 100 (non-cytotoxic).

5-FU: 5-Fluorouracil.